NeuroSense TherapeuticsNRSN -0.21%31 EV-to-FCF is -3.57 as of Jun. 27, 2026. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 333 Biotechnology companies, NeuroSense Therapeutics ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NeuroSense Therapeutics's Enterprise Value is $27.42 Mil.
NeuroSense Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.68 Mil. Therefore, NeuroSense Therapeutics's EV-to-FCF for today is -3.57.
The historical rank and industry rank for NeuroSense Therapeutics's EV-to-FCF or its related term are showing as below:
NRSN'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.57 Med: 0 Max: 0
Current: -3.57
NRSN's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs NRSN: -3.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NeuroSense Therapeutics's PE Ratio (TTM) for today is calculated as:
NeuroSense Therapeutics's share price for today is $0.7593.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NeuroSense Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NeuroSense Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroSense Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NeuroSense Therapeutics's EV-to-FCF falls into.
NeuroSense Therapeutics's current Enterprise Value is $27.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NeuroSense Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroSense Therapeutics (NRSN) has a EV-to-FCF of -3.57 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NeuroSense Therapeutics and its competitors. According to the industry distribution chart, NeuroSense Therapeutics ranks #999999 out of 333 companies in the Biotechnology industry.
Is NeuroSense Therapeutics' EV-to-FCF too high?
NeuroSense Therapeutics' current EV-to-FCF is -3.57. Based on the distribution chart, NeuroSense Therapeutics ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' EV-to-FCF compare to SNTI and LSTA?
According to the Biotechnology industry distribution chart, NeuroSense Therapeutics ranks #999999 out of 333 companies for EV-to-FCF. This places NeuroSense Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NeuroSense Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroSense Therapeutics's current EV-to-FCF is -3.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current EV-to-FCF of -3.57. The current EV-to-FCF is -3.57. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current EV-to-FCF is -3.57 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score
Get the complete analysis for NRSN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRSN has been successfully added to your 
